Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up

Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up ar...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 110; no. 9; pp. 2040 - 2054
Main Authors:	Portuguese, Andrew J., Huang, Jennifer J., Jeon, Yein, Taheri, Mahnoosh, Albittar, Aya, Liang, Emily C., Hirayama, Alexandre V., Kimble, Erik L., Iovino, Lorenzo, Poh, Christina, Gopal, Ajay K., Shadman, Mazyar, Till, Brian G., Milano, Filippo, Chapuis, Aude G., Otegbeye, Folashade, Cassaday, Ryan D., Basom, Ryan S., Wu, Qian Vicky, Maloney, David G., Gauthier, Jordan
Format:	Journal Article
Language:	English
Published:	Italy Fondazione Ferrata Storti 01.09.2025 Ferrata Storti Foundation
Subjects:	Adult Aged Aged, 80 and over Antigens, CD19 - therapeutic use Biological Products Cell Therapy & Immunotherapy Female Follow-Up Studies Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Male Middle Aged Receptors, Chimeric Antigen Retrospective Studies Tissue Extracts - adverse effects Tissue Extracts - therapeutic use Treatment Outcome
ISSN:	0390-6078, 1592-8721, 1592-8721
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!